AKCA - Akcea Therapeutics, Inc.
We couldn't determine Recommendation based on the data we have.

Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Akcea Therapeutics, Inc. (AKCA) -
Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Damien McDevitt
Employees - 294

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.